Clinical trial
Efficacy and Safety of Asenapine Using an Active Control in Subjects With…
NCT00212771 · Organon and Co, Industry · Completed
Key facts
| NCT number | NCT00212771 |
|---|---|
| Title | Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846) |
| Official title | Long-Term Efficacy and Safety Evaluation of Asenapine (10-20 mg/Day) in With Schizophrenia or Schizoaffective Disorder, in a Multicenter Trial Using (10-20 mg/Day) as a Control |
| Acronym | ACTAMESA |
| Lead sponsor | Organon and Co, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | asenapine, olanzapine |
| Enrollment | 440 |
| Start date | Sep 1, 2004 |
| Primary completion | Sep 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Feb 16, 2022 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: